United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock ...

UTHR currently has a forward P/E ratio of 12.63, while ZTS has a forward P/E of 27.56. We also note that UTHR has a PEG ratio of 0.92. This metric is used similarly to the famous P/E ratio, but the ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

FDA clears United Therapeutics for human trials of pig-to-human kidney transplants. Trial involves gene-edited pig kidneys ...

Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...

Get Our Latest Analysis on United Therapeutics United Therapeutics Price Performance NASDAQ UTHR opened at $351.17 on Friday. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - United Therapeutics (NASDAQ:UTHR) Corporation (NASDAQ: UTHR) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a ...

(RTTNews) - United Therapeutics Corp. (UTHR), a public benefit corporation, announced Monday that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application ...